Dupixent CTCLNEW MDL
Boston Sci. SCSNEW MDL
AI Chatbot Harm
NEWQUIET
Roundup
ACTIVE
AFFF
ACTIVE
Depo-Provera
ACTIVE
Talc
ACTIVE
PFAS
ACTIVE
NEC Formula
ACTIVE
Bard Hernia Mesh
QUIET
Covidien Hernia Mesh
ACTIVE
Camp Lejeune
ACTIVE
Paraquat
QUIET
Social Media
ACTIVE
PowerPort
ACTIVE
EtO Sterilization
ACTIVE
Hair Relaxer
ACTIVE
Paragard
ACTIVE
Suboxone Teeth
ACTIVE
Uber Assault
ACTIVE
Lyft Assault
ACTIVE
Ozempic Gastroparesis
ACTIVE
Ozempic NAION
MONITOR
Church Abuse
ACTIVE
1,4-Dioxane
ACTIVE
Hotel Trafficking
ACTIVE
Boy Scouts
QUIET
LDS Abuse
ACTIVE
Keytruda
ACTIVE
Tylenol
QUIET
Assembly of God
MONITOR
Video Game Addiction
MONITOR
CA Women's Prisons
ACTIVE
Zantac
ACTIVE
ByHeart Formula
MONITOR
Cartiva
ACTIVE
Roblox
ACTIVE
Sports Betting
MONITOR
Baby Food Metals
ACTIVE
Benzene Litigation
ACTIVE
Discord Abuse
ACTIVE
Social Media Sextortion
MONITOR
UPF Litigation
MONITOR
43Tracked
28Active
0Pending
Navigation
Dupixent CTCLNEW MDL
Boston Sci. SCSNEW MDL
AI Chatbot Harm
NEWQUIET
Roundup
ACTIVE
AFFF
ACTIVE
Depo-Provera
ACTIVE
Talc
ACTIVE
PFAS
ACTIVE
NEC Formula
ACTIVE
Bard Hernia Mesh
QUIET
Covidien Hernia Mesh
ACTIVE
Camp Lejeune
ACTIVE
Paraquat
QUIET
Social Media
ACTIVE
PowerPort
ACTIVE
EtO Sterilization
ACTIVE
Hair Relaxer
ACTIVE
Paragard
ACTIVE
Suboxone Teeth
ACTIVE
Uber Assault
ACTIVE
Lyft Assault
ACTIVE
Ozempic Gastroparesis
ACTIVE
Ozempic NAION
MONITOR
Church Abuse
ACTIVE
1,4-Dioxane
ACTIVE
Hotel Trafficking
ACTIVE
Boy Scouts
QUIET
LDS Abuse
ACTIVE
Keytruda
ACTIVE
Tylenol
QUIET
Assembly of God
MONITOR
Video Game Addiction
MONITOR
CA Women's Prisons
ACTIVE
Zantac
ACTIVE
ByHeart Formula
MONITOR
Cartiva
ACTIVE
Roblox
ACTIVE
Sports Betting
MONITOR
Baby Food Metals
ACTIVE
Benzene Litigation
ACTIVE
Discord Abuse
ACTIVE
Social Media Sextortion
MONITOR
UPF Litigation
MONITOR
43Tracked
28Active
0Pending
LexGenius Logo
LexGeniusYour Edge in Mass Litigation
PricingDaily DocketTrack litigations freeSign in
LexGenius

LexGenius

Your Edge in Mass Litigation

DisclaimerAcceptable UseTermsPrivacyCookie PolicySupport

© 2026 LexGenius. All rights reserved.

Active MDL61 eventsMedical Nutrition

NEC Baby Formula

Pharmaceutical · claims that premature infant formula increased necrotizing enterocolitis risk

Defendant

Abbott Laboratories

MDL / Track

MDL 3026

N.D. Ill.

Judge

Judge Rebecca R. Pallmeyer

Plaintiffs

769 pending

Bellwether / Trial

  • $495 million verdict (July 2024, Missouri state court)
  • $60 million verdict (March 2024, Illinois state court)
  • three defense wins on summary judgment in MDL bellwethers (2025)

Settlement Status

  • No global settlement
  • defendants proposed second wave bellwether schedule (Aug. 2026, Nov. 2026, Feb. 2027)
Home/Torts/NEC Baby Formula
SharePost on XShare on BlueskyShare on LinkedInShare on FacebookEmail

Track litigations for free. Save this matter, capture notes, and monitor live signals.

Sign in
← Torts Case overview Litigation status Geographic exposure Key defendants Timeline Statute of limitations Live activity Leadership News PubMed openFDA Court filings

Case overview

The NEC baby formula MDL (No. 3026) before Judge Rebecca Pallmeyer in the Northern District of Illinois includes approximately 769 pending cases as of January 2026, with hundreds more active in state courts. Plaintiffs allege Abbott Laboratories (Similac) and Mead Johnson/Reckitt (Enfamil) failed to warn that cow's milk-based formulas increase necrotizing enterocolitis risk in premature infants. State court litigation has produced two major plaintiff verdicts—$60 million against Mead Johnson in Illinois (March 2024) and $495 million against Abbott in Missouri (July 2024)—while defendants deny causation and challenge general causation testimony.

Causation Theory

Plaintiffs' causation theory rests on observational studies showing higher NEC rates among formula-fed versus human milk-fed preterm infants, including a 2024 Cochrane review finding donor human milk reduces NEC risk (RR 0.53, 95% CI 0.37–0.76). The mechanism remains contested: plaintiffs hypothesize cow's milk components trigger intestinal injury in immature gut mucosa, while defense experts and a September 2025 Pediatric Research review emphasize that human milk's protective factors—rather than formula toxicity—explain the differential risk, and that no conclusive human data identifies a specific toxic formula component.

Case Management Orders

Litigation status

MDL 3026 in the Northern District of Illinois remains active under Judge Rebecca R. Pallmeyer, with 769 pending cases as of January 2026. The court ordered a second wave of bellwether trials to begin August 2026 after three consecutive federal bellwethers were dismissed on summary judgment; state courts have produced $495 million and $60 million plaintiff verdicts.

MDL Track

MDL 3026

N.D. Ill.

Abbott preterm infant nutrition products liability

779 pending

State Court Activity

Significant activity in Missouri, Illinois, and California; Missouri $495M verdict vacated and retrial ordered (March 2025)

MDL 3026 Leadership

Plaintiff Leadership

Plaintiffs' Steering Committee

Elizabeth A. Kaveny

Kaveny + Kroll Trial Lawyers

elizabeth@kavenykroll.com(312) 761-5585

Russell T. Abney

Watts LLP

tabney@wattsllp.com(800) 222-0532

Alyson Steele Beridon

Herzfeld Suetholz Gastel Liniski & Wall, PLLC

aberidon@hsglw.com(615) 790-5354

Gerald J. Diaz, Jr.

Diaz Law Firm

gdiaz@diazlawfirm.com(713) 228-4100

Deborah S. Dixon

The Dixon Firm

ddixon@dixonfirm.com(205) 328-9200

James R. Dugan, II

Dugan Law Firm, APLC

jdugan@dugan-lawfirm.com(504) 648-0180

Kristine K. Kraft

Schlicter Bogard LLP

kraft@uselaws.com(314) 621-6115

Noah C. Lauricella

Goldenberg Lauricella PLLC

nlauricella@ggtriallaw.com(215) 545-0008

Ellen A. Presby

Ferrer Poirot Feller

epresby@fpflaw.com(718) 238-0830

Pearl A. Robertson

Irpino Avin & Hawkins

probertson@irpinolaw.com(985) 580-2759

John F. Romano

Romano Law Group

jromano@romanolawgroup.com(312) 649-9800

Plaintiffs' Co-Lead Counsel

Timothy J. Becker

Johnson // Becker, PLLC

tbecker@johnsonbecker.com(612) 436-1804

C. Andrew Childers

Levin, Papantonio, Proctor, Buchanan, O'Brien, Barr & Mougey, P.A.

achilders@levinlaw.com(850) 435-7000

Diandra S. Debrosse

DiCello Levitt LLP

fu@dicellolevitt.com(205) 328-9200

Wendy Fleishman

Lieff Cabraser Heimann & Bernstein, LLP

wfleishman@lchb.com(212) 355-9500

José M. Rojas

Levin, Rojas, Camassar & Reck, LLC

jrojas@lrcr.law(203) 213-7058

Defense Leadership

Defense Co-Liaison Counsel

Meir Feder

Jones Day LLP

mfeder@jonesday.com+1.212.326.7870

Defense Lead Counsel

Stephanie E. Parker

Jones Day LLP

separker@jonesday.com+1.202.879.3939

Geographic exposure

Approximately 370,000 premature births annually in U.S. (10% of 3.7 million births); MDL 3026 (Judge Rebecca Pallmeyer, N.D. Ill.) holds 761-769 pending federal cases with 950 total filings, while state court filings now exceed MDL volume. Manufacturers Abbott Laboratories (Similac) and Mead Johnson/Reckitt (Enfamil) face nationwide exposure across all 50 states.

  • Illinois

    Madison County affirmed as key state court venue for thousands of NEC lawsuits against Abbott Laboratories and Mead Johnson; Illinois Appellate Court rejected defendants' venue transfer attempts June 4, 2025

  • Missouri

    $495 million verdict against Abbott Labs in Missouri state court 2024 — largest NEC verdict to date; Missouri case returned to state court per Judge Pallmeyer ruling

  • New Jersey

    Kansas City family filed NEC lawsuit in New Jersey state court alleging premature infant developed NEC after cow's milk-based formula feeding in New Jersey NICU

  • Florida

    Jacksonville family filed new complaint in MDL 3026; premature infant born at 27 weeks, 2+ pounds, developed NEC after Similac feeding in NICU

  • Washington

    Washington state family filed MDL case August 9, 2024; infant born at 31 weeks gestation developed NEC after Similac Special Care feeding

  • Massachusetts

    Winchester Hospital identified as site of premature birth in active NEC litigation; case involves Similac products

  • California

    State-level JCCP proceedings ongoing; discovery disputes continue in California state court parallel to federal MDL

  • Pennsylvania

    Plaintiffs suffered procedural setback in removal fight to federal court; cases remain in active litigation status

Key defendants

Abbott Laboratories

Role: Manufacturer

Lost $495M Missouri state verdict but won third consecutive MDL bellwether trial October 2025. Daubert motions to exclude plaintiffs' experts denied by Judge Pallmeyer in MDL 3026. Illinois Appellate Court rejected venue transfer bids June 2025, keeping cases in Madison County.

Mead Johnson & Company, LLC

Role: Manufacturer

Reckitt subsidiary facing parallel exposure. Bellwether sequence set with Inman v. Mead Johnson first. No reported trial wins yet; settlement posture unclear.

St. Louis Children's Hospital

Role: Institutional Defendant

Named in Whitfield v. St. Louis Children's Hospital, rare provider-targeted case tried in Missouri. Defense verdict returned—suggesting hospitals may resist settlement unless specific feeding-protocol failures alleged.

DefendantRoleIntelligence Note
Abbott LaboratoriesManufacturerLost $495M Missouri state verdict but won third consecutive MDL bellwether trial October 2025. Daubert motions to exclude plaintiffs' experts denied by Judge Pallmeyer in MDL 3026. Illinois Appellate Court rejected venue transfer bids June 2025, keeping cases in Madison County.
Mead Johnson & Company, LLCManufacturerReckitt subsidiary facing parallel exposure. Bellwether sequence set with Inman v. Mead Johnson first. No reported trial wins yet; settlement posture unclear.
St. Louis Children's HospitalInstitutional DefendantNamed in Whitfield v. St. Louis Children's Hospital, rare provider-targeted case tried in Missouri. Defense verdict returned—suggesting hospitals may resist settlement unless specific feeding-protocol failures alleged.

Timeline

  1. 2022-04

    MDL 3026 Formed in N.D. Ill.

    Judicial Panel on Multidistrict Litigation consolidated NEC infant formula lawsuits into MDL 3026 before Judge Rebecca Pallmeyer in the Northern District of Illinois. Initial transfer included approximately 97 cases against Abbott Laboratories (Similac) and Mead Johnson (Enfamil).

  2. 2023-05

    Science Day Proceedings Held

    Parties presented medical and scientific evidence on general causation issues at Science Day proceedings in MDL 3026, as ordered by Judge Pallmeyer.

  3. 2024-03

    $60M Verdict in Illinois State Court

    St. Clair County, Illinois jury awarded $60 million to plaintiff Jasmine Watson in Enfamil NEC case against Mead Johnson. Verdict believed to be largest compensatory award in county history at that time.

  4. 2024-07

    $495M Verdict in Missouri State Court

    Missouri state court jury awarded $495 million against Abbott Laboratories in Similac NEC case. Largest verdict to date in NEC litigation.

  5. 2024-10

    Defense Verdict in Missouri; New Trial Ordered

    Missouri jury returned defense verdict for Abbott and Reckitt in Whitfield v. Abbott Laboratories. Circuit Judge Michael Noble subsequently granted motion for new trial on March 13, 2025, citing erroneous evidentiary rulings.

  6. 2025-05

    First MDL Bellwether Dismissed

    Judge Pallmeyer granted summary judgment to Abbott in Mar v. Abbott Laboratories, Case No. 1:22-cv-00232, the first MDL 3026 bellwether trial. Dismissal based in part on unavailability of donor milk or human milk fortifier at treating hospital.

  7. 2025-07

    Second MDL Bellwether Dismissed

    Judge Pallmeyer granted summary judgment to defendants in second MDL bellwether case, continuing defense winning streak in federal court.

  8. 2025-10

    Third Consecutive MDL Bellwether Dismissed

    Judge Pallmeyer granted summary judgment to Abbott in third straight MDL bellwether trial, marking third consecutive defense win in federal proceedings.

  9. 2026-01

    MDL Case Count Stabilizes Near 770

    MDL 3026 pending case count reported at 769 active cases with 950 total filings. Fourth bellwether trial Inman v. Mead Johnson & Company, LLC rescheduled for July 6, 2026.

Statute of limitations

Discovery rule applicability varies by state and materially affects NEC cases where diagnosis may post-date NICU discharge by months or years. Source [2] and [3] emphasize discovery rule may extend filing deadlines when harm was not immediately discoverable. Source [4] notes Kentucky and Louisiana have 1-year deadlines (shortest); Maine and North Dakota 6 years; Missouri 5 years. No global tolling agreement confirmed in sources; individual tolling agreements may exist. MDL 3026 centralized in N.D. Ill. per JPML order January 2024.

⚠ 1 state with critical SOL — act immediately

Illinois

2 years from discovery

Rule: 735 ILCS 5/13-202(a) (product liability); discovery rule applies per standard Illinois tort accrual

Discovery: Accrues when plaintiff knew or reasonably should have known of injury and its causal connection to formula

Home to Abbott Laboratories and Mead Johnson headquarters; venue of choice for many filings. Source [2] confirms 2-year deadline with discovery rule extension. Minority tolling: 735 ILCS 5/13-211 suspends until age 18, then 2 years to file

Florida

2 years from injury

Rule: Fla. Stat. § 95.11(3)(a) (product liability)

Discovery: Limited; state may allow exceptions under certain circumstances per source [1]

Source [1] confirms 2-year deadline per § 95.11. Minority tolling: § 95.051 gives minors additional time. Source [1] notes exceptions for parents under certain circumstances—speaking to lawyer advised

California

2 years from injury

Rule: Cal. Code Civ. Proc. § 335.1

Source [4] confirms 2-year deadline. No minority tolling for product liability; parents must file derivative claims within 2 years

Texas

2 years from injury

Rule: Tex. Civ. Prac. & Rem. Code § 16.003(a)

Source [4] confirms 2-year deadline among most states. Minority tolling typically until age 18, then 2 years

New York

3 years from injury

Rule: N.Y. C.P.L.R. § 214

Source [4] confirms 3-year deadline. Infant tolling: § 208 suspends until age 18, then 3 years

Pennsylvania

2 years from injury

Rule: 42 Pa. Cons. Stat. § 5524

Source [4] confirms 2-year deadline. Minority tolling: § 5533 tolls until age 18, then 2 years

⚠Michigan

3 years from injury

Rule: Mich. Comp. Laws § 600.5805

Source [4] confirms 3-year deadline. Minority tolling: § 600.5851 tolls until age 18, then 1 year—short post-minority window creates intake urgency

StateSOLRuleDiscovery RuleNotes
Illinois2 years from discovery735 ILCS 5/13-202(a) (product liability); discovery rule applies per standard Illinois tort accrualAccrues when plaintiff knew or reasonably should have known of injury and its causal connection to formulaHome to Abbott Laboratories and Mead Johnson headquarters; venue of choice for many filings. Source [2] confirms 2-year deadline with discovery rule extension. Minority tolling: 735 ILCS 5/13-211 suspends until age 18, then 2 years to file
Florida2 years from injuryFla. Stat. § 95.11(3)(a) (product liability)Limited; state may allow exceptions under certain circumstances per source [1]Source [1] confirms 2-year deadline per § 95.11. Minority tolling: § 95.051 gives minors additional time. Source [1] notes exceptions for parents under certain circumstances—speaking to lawyer advised
California2 years from injuryCal. Code Civ. Proc. § 335.1—Source [4] confirms 2-year deadline. No minority tolling for product liability; parents must file derivative claims within 2 years
Texas2 years from injuryTex. Civ. Prac. & Rem. Code § 16.003(a)—Source [4] confirms 2-year deadline among most states. Minority tolling typically until age 18, then 2 years
New York3 years from injuryN.Y. C.P.L.R. § 214—Source [4] confirms 3-year deadline. Infant tolling: § 208 suspends until age 18, then 3 years
Pennsylvania2 years from injury42 Pa. Cons. Stat. § 5524—Source [4] confirms 2-year deadline. Minority tolling: § 5533 tolls until age 18, then 2 years
⚠Michigan3 years from injuryMich. Comp. Laws § 600.5805—Source [4] confirms 3-year deadline. Minority tolling: § 600.5851 tolls until age 18, then 1 year—short post-minority window creates intake urgency

Live intelligence

AI litigation brief

NEC Baby Formula remains active mdl with 61 current signals in the accepted feed.

Overview

MDL 3026 in the Northern District of Illinois remains active under Judge Rebecca R. Pallmeyer, with 769 pending cases as of January 2026. The court ordered a second wave of bellwether trials to begin August 2026 after three consecutive federal bellwethers were dismissed on summary judgment; state courts have produced $495 million and $60 million plaintiff verdicts.

Key developments

  • PACER court filing on Dec 31: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
  • TribLIVE.com news on Jun 8: Similac baby formula maker sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com
  • PubMed research on Dec 1: Antenatal Bartter Syndrome Type 4a: Ibuprofen Treatment for a Challenging Case of Very Low Birth Weight Infant.

Trajectory

Court filings and press coverage are both active in MDL 3026, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.

Editorial intelligence

MDL 3026 should stay on the lead docket watch because it is the primary consolidation vehicle for NEC Formula.

Generated Jun 13, 2026, 9:00 AM UTC

61 events detected

Google News (24)

  • Similac baby formula maker sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com

    TribLIVE.comJun 8, 2026, 9:07 PM UTC
  • NEC Baby Formula Lawsuit 2026 Update: What Families Need to Know - Edgar Snyder & Associates

    Edgar Snyder & AssociatesMay 28, 2026, 7:00 AM UTC
  • Preterm Infant Formula Argument Focuses on Feeding Alternatives - Bloomberg Law News

    Bloomberg Law NewsMay 20, 2026, 7:00 AM UTC
  • Nestle and Danone face fresh scrutiny over infant formula recalls - Reuters

    ReutersMay 20, 2026, 7:00 AM UTC
  • Judge sets up high stakes baby formula NEC trial vs Mead Johnson - The Black Chronicle

    The Black ChronicleMay 17, 2026, 7:00 AM UTC
  • Abbott Securities Lawsuit Deepens Infant Formula Risks For Shareholders - Sahm

    SahmMay 14, 2026, 10:58 AM UTC
  • Abbott loses appeal of nearly $500 million infant formula verdict - Crain's Chicago Business

    Crain's Chicago BusinessMay 6, 2026, 7:00 AM UTC
  • FDA Infant Formula Testing and NEC Lawsuits Explained - The Legal Examiner

    The Legal ExaminerMay 5, 2026, 7:00 AM UTC
  • Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula - Chicago Tribune

    Chicago TribuneMay 5, 2026, 7:00 AM UTC
  • Missouri appeals court upholds $495M ruling against Abbott in baby formula case - Seeking Alpha

    Seeking AlphaMay 5, 2026, 7:00 AM UTC
  • Juries and Judges at Odds in Preterm Infant Formula Cases - The National Law Review

    The National Law ReviewApr 30, 2026, 7:00 AM UTC
  • FDA search for baby formula contamination finds little - Crain's Chicago Business

    Crain's Chicago BusinessApr 29, 2026, 7:00 AM UTC
  • Major NEC Verdict Could Shape Future Formula Lawsuits - The Legal Examiner

    The Legal ExaminerApr 17, 2026, 5:37 PM UTC
  • US preterm feed verdict revives call for infant formula warnings in India - India Today

    India TodayApr 16, 2026, 7:00 AM UTC
  • Illinois jury awards additional $17M in baby formula lawsuits against Abbott - Top Class Actions

    Top Class ActionsApr 15, 2026, 5:07 PM UTC
  • Abbott Jury Awards at Least $53 Million in Infant-Formula Trial - Bloomberg.com

    Bloomberg.comApr 10, 2026, 8:52 PM UTC
  • Abbott Laboratories to pay $70M in damages in infant formula lawsuit - Chicago Sun-Times

    Chicago Sun-TimesApr 10, 2026, 7:00 AM UTC
  • Jury orders Abbott to pay $70 million in preterm infant formula trial, company says - Reuters

    ReutersApr 10, 2026, 7:00 AM UTC
  • Chicago jury awards millions to families after babies fall ill after consuming Abbott Laboratories formula - ABC7 Chicago

    ABC7 ChicagoApr 10, 2026, 7:00 AM UTC
  • Abbott Laboratories must pay at least $53 million in cases over infant formula, jury decides - Chicago Tribune

    Chicago TribuneApr 10, 2026, 12:47 AM UTC
  • Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says - Yahoo Finance

    Yahoo FinanceApr 9, 2026, 7:00 AM UTC
  • Jury Deliberates in Lawsuit Over Abbott Formula Linked to Premature Baby Illness - National Today

    National TodayApr 9, 2026, 6:42 AM UTC
  • Jury deliberating in Cook County case over Abbott Laboratories’ formula for premature babies - Chicago Tribune

    Chicago TribuneApr 9, 2026, 12:04 AM UTC
  • Inside the High-Stakes Corporate Fight Over Feeding Preterm Babies - KFF Health News

    KFF Health NewsMar 30, 2026, 9:00 AM UTC
StudyPubMed
Detected Jun 9, 2026, 9:01 AM UTC

Antenatal Bartter Syndrome Type 4a: Ibuprofen Treatment for a Challenging Case of Very Low Birth Weight Infant.

Pediatrics international : official journal of the Japan Pediatric Society • Oshiro M • PMID 41988811 • Journal Article.

Confidence 74%Published Dec 1, 2026, 12:00 AM UTCSource →
StudyPubMed
Detected Jun 13, 2026, 9:01 AM UTC

Study of the gut microbiome profile in full-term infants with necrotizing enterocolits.

World journal of clinical pediatrics • Abdelwahab IA • PMID 42220946 • Journal Article.

Confidence 74%Published Jun 9, 2026, 12:00 AM UTCSource →
StudyPubMed
Detected Jun 13, 2026, 9:01 AM UTC

From Powder to Pathogen: A Systematic Review of Detection, Pathogenicity, and Mitigation of Cronobacter sakazakii in Infant Formula.

International journal of microbiology • Mohanto NC • PMID 42266447 • Journal Article.

Confidence 74%Published Jun 7, 2026, 12:00 AM UTCSource →
StudyPubMed
Detected Jun 13, 2026, 9:01 AM UTC

SIGIRR-TWIST1 axis regulates barrier function in neonatal intestine.

Cellular and molecular gastroenterology and hepatology • Sampath V • PMID 42248551 • Journal Article.

Confidence 74%Published Jun 4, 2026, 12:00 AM UTCSource →
StudyPubMed
Detected Jun 13, 2026, 9:01 AM UTC

The RNA-binding protein Imp1 promotes a Spdef transcriptional program and mucus fucosylation during necrotizing enterocolitis.

American journal of physiology. Gastrointestinal and liver physiology • Andres SF • PMID 42242905 • Journal Article.

Confidence 74%Published Jun 4, 2026, 12:00 AM UTCSource →

No recent FDA signals. Monitoring is active — this section updates automatically.

PACERJPMLmdl-3026-stubDec 31, 2099, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket filed in JPML: The plaintiffs are suing the manufacturers of 'Similac' and 'Enfamil' cow's milk-based infant feeding products, alleging that these products caused a severe gastrointestinal condition called necrotizing enterocolitis (NEC) in the infant plaintiff L.K. The lawsuit claims that there were safer human m

PACERILND1:26-cv-06776Jun 8, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from ILND: COMPLAINT filed by Tanner Tejcka; Jury Demand. Filing fee $ 405, receipt number AILNDC-25225330.(Wexler, Noah) (Entered: 06/08/2026)

PACERPAWD2:26-cv-01224Jun 5, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from PAWD: COMPLAINT against ABBOTT LABORATORIES INC. (Filing fee, including Administrative fee, $405, receipt number APAWDC-9631383), filed by PARIS WRIGHT, DEMETRIUS WILLIAMS. (Fleishman, Wendy) (Entered: 06/05/2026)

PACERGAMD5:26-cv-00227Jun 5, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from GAMD: COMPLAINT against Abbott Laboratories., Inc. Fee paid: Receipt # AGAMDC-5306886, $405 filed by Rikesja Pye (SMALLEY, ROBERT) (Entered: 06/05/2026)

PACERILND1:26-cv-06621Jun 4, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from ILND: COMPLAINT filed by MICHAEL TRAHAN, AMY CLARE TRAHAN; Jury Demand. Filing fee $ 405, receipt number AILNDC-25208329. (Attachments: # 1 Civil Cover Sheet, # 2 Appendix Cover Sheet)(Plymale, Douglas) (Entered: 06/04/2026)

PACERILND1:26-cv-06561Jun 3, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from ILND: COMPLAINT filed by Merissa Mahan; Jury Demand. Filing fee $ 405, receipt number AILNDC-25202413.(Wexler, Noah) (Entered: 06/03/2026)

PACERCTD3:26-cv-00879Jun 3, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from CTD: COMPLAINT against ABBOTT LABORATORIES INC ( Filing fee $405 receipt number ACTDC-8631636.), filed by Lakeesha Felicien.(Duhl, Glenn) (Entered: 06/03/2026)

PACERILSD3:26-cv-00775Jun 2, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from ILSD: NOTICE OF REMOVAL from The Circuit Court of the St. Clair County, Illinois, case number 2026LA000400 ( Filing fee $ 405 receipt number AILSDC-5919354), filed by Mead Johnson Nutrition Company, Mead Johnson & Company, LLC. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(Anscombe, Anthony) (Enter

PACERILSD3:26-cv-00779Jun 2, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from ILSD: NOTICE OF REMOVAL from The Circuit Court of St. Clair County, Illinois, case number 2026LA000409 ( Filing fee $ 405 receipt number AILSDC-5919750), filed by Mead Johnson Nutrition Company, Mead Johnson & Company, LLC. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(Anscombe, Anthony) (Entered:

PACERILND1:26-cv-06411Jun 2, 2026, 12:00 AM UTC

Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation

PACER docket entry from ILND: COMPLAINT with JURY DEMAND against Abbott Laboratories, Inc., filed by Kayla O'Malley. (Attachments: # 1 Civil Cover Sheet Civil Cover Sheet) (Karon, Daniel) [Transferred from Ohio Southern on 6/2/2026.] (Entered: 05/14/2026)

Sign in to view all 12 filings

Workbench

Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.

LexGenius Ranking

80Score

Court, news, and regulatory activity are elevated

Evidence20 / 20
Momentum20 / 20
Exposure14 / 20
Regulatory12 / 20
Legal20 / 20

Monitoring

Live

monitoring

Last: Jun 13, 2026, 9:00 AM UTC

Next: 09:35

Source Monitoring

PACER

4m 35s

PACER

35s

Google News

4m 35s

FAERS

9m 35s

PubMed

9m 35s

Event feed

61

events detected

Google NewsPACERPubMed

AI Brief

NEC Baby Formula remains active mdl with 61 current signals in the accepted feed.

Overview

MDL 3026 in the Northern District of Illinois remains active under Judge Rebecca R. Pallmeyer, with 769 pending cases as of January 2026. The court ordered a second wave of bellwether trials to begin August 2026 after three consecutive federal bellwethers were dismissed on summary judgment; state courts have produced $495 million and $60 million plaintiff verdicts.

Key developments

PACER court filing on Dec 31: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation. ‖ TribLIVE.com news on Jun 8: Similac baby formula maker sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com. ‖ PubMed research on Dec 1: Antenatal Bartter Syndrome Type 4a: Ibuprofen Treatment for a Challenging Case of Very Low Birth Weight Infant..

Generated Jun 13, 2026, 9:00 AM UTC

Tracked MDLs

MDL 3026

N.D. Ill.

Abbott preterm infant nutrition products liability

← Previous

PFAS

Captures forever-chemical contamination litigation, rulemaking, and public-health reporting affecting PFAS exposure.

Next →

Bard Hernia Mesh

Monitors Bard and Davol hernia mesh MDL 2846, bellwether activity, and device-safety reporting tied to polypropylene mesh claims.